Roche Holding AG's group revenues may have taken a thumping in the second quarter due to the expected decline in sales of COVID-19 products at its diagnostics division
Roche Eyes More Growth Opportunities For Vabysmo
Ophthalmology Drug Sales Soar In Q2
The Swiss behemoth’s top five growth drivers – Vabysmo, Ocrevus, Hemlibra, Evrysdi and Phesgo – are selling well and softening the loss in earnings from products that boomed during COVID-19.
More from Earnings
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.